The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35

A truncated fragment of p35, the Cdk5 kinase regulatory protein (TFP5), inhibits specifically hyperactive Cdk5/p25 activity and rescues the Alzheimer’s disease and Parkinson’s disease phenotype in model mice. To account for the selective inhibition of Cdk5/p25 activity, the p10 N-terminal domain of p35, absent in p25, spares Cdk5/p35.

• Publication year

  2016

• Venue

  Molecular Biology of the Cell

• Publication date

  2016-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1091/mbc.E15-12-0857PMID 27630261PMCID 5170856
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Computational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore

  2016cited by this paper
• CDK5 activator protein p25 preferentially binds and activates GSK3β

  2014cited by this paper
• A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice

  2013cited by this paper
• Specific Inhibition of p25/Cdk5 Activity by the Cdk5 Inhibitory Peptide Reduces Neurodegeneration In Vivo

  2013cited by this paper
• p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity

  2012influential reference
• A 24-Residue Peptide (p5), Derived from p35, the Cdk5 Neuronal Activator, Specifically Inhibits Cdk5-p25 Hyperactivity and Tau Hyperphosphorylation*

  2010cited by this paper
• Identification of p10 as a neurotoxic product generated from the proteolytic cleavage of the neuronal Cdk5 activator

  2010cited by this paper
• Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP.

  2010cited by this paper
• The neuronal p35 activator of Cdk5 is a novel F-actin binding and bundling protein

  2010cited by this paper
• Evaluation of the Interaction of Cyclin-Dependent Kinase 5 with Activator p25 and with p25-Derived Inhibitor CIP

  2010cited by this paper
• Explaining the inhibition of cyclin-dependent kinase 5 by peptides derived from p25 with molecular dynamics simulations and MM-PBSA

  2010influential reference
• Targeting Cdk5 Activity in Neuronal Degeneration and Regeneration

  2009cited by this paper
• Making a neuron: Cdk5 in embryonic and adult neurogenesis.

  2009cited by this paper
• [p35 and p25 expressions and Cdk5 kinase activity in primary cultured rat hippocampal neurons with X-ray exposure].

  2009cited by this paper
• Cyclin-Dependent Kinase 5 Supports Neuronal Survival through Phosphorylation of Bcl-2

  2008cited by this paper
• Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5

  2007cited by this paper
• Microtubule Association of the Neuronal p35 Activator of Cdk5*

  2007cited by this paper
• The complex p25/Cdk5 kinase in neurofibrillary degeneration and neuronal death: The missing link to cell cycle

  2007cited by this paper
• New approaches to the discovery of cdk5 inhibitors.

  2007cited by this paper
• When good Cdk5 turns bad.

  2006cited by this paper
• Cyclin‐dependent kinase 5 in synaptic plasticity, learning and memory

  2006cited by this paper
• Identification of Nuclear Import Mechanisms for the Neuronal Cdk5 Activator*

  2006cited by this paper
• Is there a role of the cyclin-dependent kinase 5 activator p25 in Alzheimer's disease?

  2005cited by this paper
• A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons

  2005cited by this paper
• Mechanism of CDK5/p25 binding by CDK inhibitors.

  2005cited by this paper
• Cdk5, a therapeutic target for Alzheimer's disease?

  2004cited by this paper
• Co-purification and localization of Munc18-1 (p67) and Cdk5 with neuronal cytoskeletal proteins.

  2004cited by this paper
• Cdk5 deregulation in the pathogenesis of Alzheimer's disease.

  2004cited by this paper
• Protein-Protein Interactions in Cdk5 Regulation and Function

  2003influential reference
• Role of Cdk5 in Neuronal Signaling, Plasticity, and Drug Abuse

  2003cited by this paper
• Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.

  2003cited by this paper
• Cyclin-Dependent Kinase 5 and Neuronal Migration in the Neocortex

  2003cited by this paper
• Cdk5: A New Player at Synapses

  2003cited by this paper
• Role of cdk5 in the Pathogenesis of Alzheimer’s Disease

  2003cited by this paper
• Cdk5 as a drug target for the treatment of Alzheimer’s disease

  2002cited by this paper
• The Protein SET Binds the Neuronal Cdk5 Activator p35 nck5a and Modulates Cdk5/p35 nck5a Activity*

  2002cited by this paper
• Cyclin‐dependent kinase 5 (cdk5) activation requires interaction with three domains of p35

  2002cited by this paper
• A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.

  2002cited by this paper
• Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells

  2002cited by this paper
• Structure and Regulation of the CDK5-p25nck5a Complex

  2001cited by this paper
• Structure and regulation of the CDK5-p25(nck5a) complex.

  2001cited by this paper
• Structural Insights into Cdk5 activation by a neuronal Cdk5 activator.

  2001cited by this paper
• Cyclin-dependent protein kinase 5 (Cdk5) and the regulation of neurofilament metabolism.

  2001cited by this paper
• A decade of CDK5

  2001cited by this paper
• Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions.

  2001cited by this paper
• Cdk5/p25nck5a interaction with synaptic proteins in bovine brain

  2000cited by this paper
• Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells.

  2000cited by this paper
• Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.

  2000cited by this paper
• Cdk5 and MAPK are associated with complexes of cytoskeletal proteins in rat brain.

  2000cited by this paper
• Calpain-dependent Proteolytic Cleavage of the p35 Cyclin-dependent Kinase 5 Activator to p25*

  2000cited by this paper
• Neurotoxicity induces cleavage of p35 to p25 by calpain

  2000cited by this paper
• Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration

  1999cited by this paper
• Regulation of Munc-18/Syntaxin 1A Interaction by Cyclin-dependent Kinase 5 in Nerve Endings*

  1998cited by this paper
• Association of Neurofilament Proteins with Neuronal Cdk5 Activator*

  1998cited by this paper
• Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death.

  1996cited by this paper
• The role of Sec1p‐related proteins in vesicle trafficking in the nerve terminal

  1996cited by this paper
• Interaction of Cyclin-dependent Kinase 5 (Cdk5) and Neuronal Cdk5 Activator in Bovine Brain (*)

  1996cited by this paper
• Molecular Characterization of a Neuronal‐Specific Protein that Stimulates the Activity of Cdk5

  1995cited by this paper
• Molecular Biology of the Cell

  1990cited by this paper

• Munc 18-1 is a multifaceted therapeutic target for Dementia.

  2025cites this paper
• The Duality of Cdk5: A Master Regulator in Neurodevelopment and a Hijacked Oncogene in Cancer

  2025cites this paper
• Investigation of the Effect of Peptide p5 Targeting CDK5-p25 Hyperactivity on Munc18-1 (P67) Regulating Neuronal Exocytosis Using Molecular Simulations.

  2024cites this paper
• TFP5 attenuates cyclin‐dependent kinase 5‐mediated islet β‐cell damage in diabetes

  2023influential citation
• Long Noncoding RNA H19 Induces Neuropathic Pain by Upregulating Cyclin-Dependent Kinase 5-Mediated Phosphorylation of cAMP Response Element Binding Protein

  2020cites this paper
• Cdk5 Inhibitory Peptide Prevents Loss of Neurons and Alleviates Behavioral Changes in p25 Transgenic Mice

  2020cites this paper
• The Role of CDK5 in Tumours and Tumour Microenvironments

  2020influential citation
• Hypoxia induces HT-22 neuronal cell death via Orai1/CDK5 pathway-mediated Tau hyperphosphorylation.

  2019cites this paper
• Overexpression of the Cdk5 inhibitory peptide in motor neurons rescue of amyotrophic lateral sclerosis phenotype in a mouse model.

  2019cites this paper
• Quantum capacitance-limited MoS2 biosensors enable remote label-free enzyme measurements.

  2018cites this paper
• Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson’s Disease Mouse Model

  2018cites this paper
• Peptides Derived from Neuronal Cell Cycle like Kinase 5 Activator p35, inNeurodegeneration; Pathology and Therapy

  2017cites this paper
• Therapeutic peptides for CNS indications: Progress and challenges.

  2017cites this paper
• Controlled bioactive compound delivery systems based on double polysaccharide film-coated microparticles for liquid products and their release behaviors

  2017cites this paper
• Peptides in Neurodegeneration ; Pathology and Therapy

  2017cites this paper